# Ormat Technologies, Inc.: financial statements, quarterly

ORA · NYSE · CIK 1296445 · [Utilities](/sectors/utilities.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ora.md) · [Financials](/companies/ora/financials.md) · [Filings](/companies/ora/filings.md) · [Insiders](/companies/ora/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ora/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [208](/filings/0001628280-24-046065.md) | [241 d](/filings/0001296445-26-000006.md) | [224](/filings/0001628280-25-023547.md) | [213](/filings/0001296445-25-000008.md) | [212](/filings/0001296445-25-000012.md) | [231 d](/filings/0001296445-26-000006.md) | [230](/filings/0001296445-26-000008.md) | [234](/filings/0001296445-26-000014.md) | [250](/filings/0001296445-25-000012.md) | [276 d](/filings/0001296445-26-000006.md) | [404](/filings/0001296445-26-000008.md) | [259](/filings/0001296445-26-000014.md) |
| Cost of revenue | $m | [148](/filings/0001628280-24-046065.md) | [163 d](/filings/0001296445-26-000006.md) | [145](/filings/0001628280-25-023547.md) | [152](/filings/0001296445-25-000008.md) | [153](/filings/0001296445-25-000012.md) | [157 d](/filings/0001296445-26-000006.md) | [157](/filings/0001296445-26-000008.md) | [177](/filings/0001296445-26-000014.md) | [186](/filings/0001296445-25-000012.md) | [197 d](/filings/0001296445-26-000006.md) | [284](/filings/0001296445-26-000008.md) | [190](/filings/0001296445-26-000014.md) |
| Gross profit | $m | [60.0](/filings/0001628280-24-046065.md) | [78.5 d](/filings/0001296445-26-000006.md) | [78.8](/filings/0001628280-25-023547.md) | [61.4](/filings/0001296445-25-000008.md) | [58.9](/filings/0001296445-25-000012.md) | [73.6 d](/filings/0001296445-26-000006.md) | [72.9](/filings/0001296445-26-000008.md) | [56.9](/filings/0001296445-26-000014.md) | [64.0](/filings/0001296445-25-000012.md) | [78.8 d](/filings/0001296445-26-000006.md) | [120](/filings/0001296445-26-000008.md) | [68.7](/filings/0001296445-26-000014.md) |
| Research and development | $m | [1.4](/filings/0001628280-24-046065.md) | [2.5 d](/filings/0001296445-26-000006.md) | [1.6](/filings/0001628280-25-023547.md) | [1.7](/filings/0001296445-25-000008.md) | [1.8](/filings/0001296445-25-000012.md) | [1.4 d](/filings/0001296445-26-000006.md) | [2.5](/filings/0001296445-26-000008.md) | [1.4](/filings/0001296445-26-000014.md) | [1.3](/filings/0001296445-25-000012.md) | [1.0 d](/filings/0001296445-26-000006.md) | [1.1](/filings/0001296445-26-000008.md) | [1.5](/filings/0001296445-26-000014.md) |
| Operating income | $m | [37.6](/filings/0001628280-24-046065.md) | [51.6 d](/filings/0001296445-26-000006.md) | [52.6](/filings/0001628280-25-023547.md) | [35.1](/filings/0001296445-25-000008.md) | [35.7](/filings/0001296445-25-000012.md) | [49.1 d](/filings/0001296445-26-000006.md) | [50.9](/filings/0001296445-26-000008.md) | [35.3](/filings/0001296445-26-000014.md) | [40.4](/filings/0001296445-25-000012.md) | [42.6 d](/filings/0001296445-26-000006.md) | [80.3](/filings/0001296445-26-000008.md) | [34.2](/filings/0001296445-26-000014.md) |
| Interest expense | $m | [25.1](/filings/0001437749-23-031120.md) | [25.8 d](/filings/0001437749-24-005322.md) | [31.0](/filings/0001437749-24-015856.md) | [33.7](/filings/0001296445-25-000008.md) | [34.8](/filings/0001296445-25-000012.md) | [34.5 d](/filings/0001296445-26-000006.md) | [34.5](/filings/0001296445-26-000008.md) | [36.7](/filings/0001296445-26-000014.md) | [35.7](/filings/0001296445-25-000012.md) | [35.0 d](/filings/0001296445-26-000006.md) | [45.0](/filings/0001296445-26-000008.md) | [43.9](/filings/0001296445-26-000014.md) |
| Income tax | $m | [(7.1)](/filings/0001628280-24-046065.md) | [8.2 d](/filings/0001296445-26-000006.md) | [(0.1)](/filings/0001628280-25-023547.md) | [(3.2)](/filings/0001296445-25-000008.md) | [(1.2)](/filings/0001296445-25-000012.md) | [(11.8) d](/filings/0001296445-26-000006.md) | [(3.8)](/filings/0001296445-26-000008.md) | [(5.5)](/filings/0001296445-26-000014.md) | [(4.3)](/filings/0001296445-25-000012.md) | [(6.7) d](/filings/0001296445-26-000006.md) | [(15.5)](/filings/0001296445-26-000008.md) | [(9.7)](/filings/0001296445-26-000014.md) |
| Net income | $m | [35.5](/filings/0001628280-24-046065.md) | [35.7 d](/filings/0001296445-26-000006.md) | [38.6](/filings/0001628280-25-023547.md) | [22.2](/filings/0001296445-25-000008.md) | [22.1](/filings/0001296445-25-000012.md) | [40.8 d](/filings/0001296445-26-000006.md) | [40.4](/filings/0001296445-26-000008.md) | [28.0](/filings/0001296445-26-000014.md) | [24.1](/filings/0001296445-25-000012.md) | [31.4 d](/filings/0001296445-26-000006.md) | [44.1](/filings/0001296445-26-000008.md) | [27.1](/filings/0001296445-26-000014.md) |
| Diluted EPS | $ per share | [0.59](/filings/0001628280-24-046065.md) | not reported | [0.64](/filings/0001628280-25-023547.md) | [0.37](/filings/0001296445-25-000008.md) | [0.36](/filings/0001296445-25-000012.md) | not reported | [0.66](/filings/0001296445-26-000008.md) | [0.46](/filings/0001296445-26-000014.md) | [0.39](/filings/0001296445-25-000012.md) | not reported | [0.71](/filings/0001296445-26-000008.md) | [0.43](/filings/0001296445-26-000014.md) |
| Basic EPS | $ per share | [0.59](/filings/0001628280-24-046065.md) | not reported | [0.64](/filings/0001628280-25-023547.md) | [0.37](/filings/0001296445-25-000008.md) | [0.37](/filings/0001296445-25-000012.md) | not reported | [0.67](/filings/0001296445-26-000008.md) | [0.46](/filings/0001296445-26-000014.md) | [0.40](/filings/0001296445-25-000012.md) | not reported | [0.72](/filings/0001296445-26-000008.md) | [0.44](/filings/0001296445-26-000014.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [78.1](/filings/0001437749-23-031120.md) | [196](/filings/0001296445-26-000006.md) | [202](/filings/0001437749-24-015856.md) | [66.3](/filings/0001628280-24-035397.md) | [88.1](/filings/0001628280-24-046065.md) | [94.4](/filings/0001296445-26-000006.md) | [113](/filings/0001628280-25-023547.md) | [88.5](/filings/0001296445-25-000008.md) | [79.6](/filings/0001296445-25-000012.md) | [147](/filings/0001296445-26-000014.md) | [655](/filings/0001296445-26-000008.md) | [514](/filings/0001296445-26-000014.md) |
| Current assets | $m | [516](/filings/0001437749-23-031120.md) | [646](/filings/0001628280-25-008531.md) | [609](/filings/0001437749-24-015856.md) | [517](/filings/0001628280-24-035397.md) | [537](/filings/0001628280-24-046065.md) | [547](/filings/0001296445-26-000006.md) | [601](/filings/0001628280-25-023547.md) | [509](/filings/0001296445-25-000008.md) | [505](/filings/0001296445-25-000012.md) | [598](/filings/0001296445-26-000014.md) | [1,082](/filings/0001296445-26-000008.md) | [1,021](/filings/0001296445-26-000014.md) |
| Total assets | $m | [5,011](/filings/0001628280-24-046065.md) | [5,208](/filings/0001628280-25-008531.md) | [5,517](/filings/0001628280-25-023547.md) | [5,507](/filings/0001296445-25-000008.md) | [5,590](/filings/0001296445-25-000012.md) | [5,666](/filings/0001296445-26-000006.md) | [5,839](/filings/0001296445-26-000008.md) | [6,016](/filings/0001296445-26-000014.md) | [6,093](/filings/0001296445-25-000012.md) | [6,247](/filings/0001296445-26-000014.md) | [6,772](/filings/0001296445-26-000008.md) | [6,788](/filings/0001296445-26-000014.md) |
| Current liabilities | $m | [540](/filings/0001437749-23-031120.md) | [537](/filings/0001628280-25-008531.md) | [546](/filings/0001437749-24-015856.md) | [531](/filings/0001628280-24-035397.md) | [566](/filings/0001628280-24-046065.md) | [598](/filings/0001296445-26-000006.md) | [619](/filings/0001628280-25-023547.md) | [731](/filings/0001296445-25-000008.md) | [655](/filings/0001296445-25-000012.md) | [738](/filings/0001296445-26-000014.md) | [1,013](/filings/0001296445-26-000008.md) | [976](/filings/0001296445-26-000014.md) |
| Total liabilities | $m | [2,596](/filings/0001437749-23-031120.md) | [2,757](/filings/0001628280-25-008531.md) | [3,030](/filings/0001437749-24-015856.md) | [3,000](/filings/0001628280-24-035397.md) | [3,066](/filings/0001628280-24-046065.md) | [3,106](/filings/0001296445-26-000006.md) | [3,244](/filings/0001628280-25-023547.md) | [3,386](/filings/0001296445-25-000008.md) | [3,440](/filings/0001296445-25-000012.md) | [3,555](/filings/0001296445-26-000014.md) | [4,054](/filings/0001296445-26-000008.md) | [4,044](/filings/0001296445-26-000014.md) |
| Long-term debt | $m | not reported | [1,990](/filings/0001437749-24-005322.md) | not reported | not reported | not reported | [2,345](/filings/0001628280-25-008531.md) | not reported | not reported | not reported | [2,661](/filings/0001296445-26-000006.md) | not reported | not reported |
| Short-term borrowings | $m | [35.0](/filings/0001437749-23-031120.md) | [100.0](/filings/0001628280-25-008531.md) | [100.0](/filings/0001437749-24-015856.md) | [100.0](/filings/0001628280-24-035397.md) | [100.0](/filings/0001628280-24-046065.md) | [100.0](/filings/0001296445-26-000006.md) | [100.0](/filings/0001628280-25-023547.md) | [100.0](/filings/0001296445-25-000008.md) | [100.0](/filings/0001296445-25-000012.md) | [100.0](/filings/0001296445-26-000014.md) | [100.0](/filings/0001296445-26-000008.md) | [100.0](/filings/0001296445-26-000014.md) |
| Shareholders' equity | $m | [2,279](/filings/0001437749-23-031120.md) | [2,315](/filings/0001628280-25-008531.md) | [2,352](/filings/0001437749-24-015856.md) | [2,371](/filings/0001628280-24-035397.md) | [2,389](/filings/0001628280-24-046065.md) | [2,425](/filings/0001296445-26-000006.md) | [2,461](/filings/0001628280-25-023547.md) | [2,493](/filings/0001296445-25-000008.md) | [2,510](/filings/0001296445-25-000012.md) | [2,544](/filings/0001296445-26-000014.md) | [2,571](/filings/0001296445-26-000008.md) | [2,598](/filings/0001296445-26-000014.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings, us-gaap:CommercialPaper
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [39.8 d](/filings/0001628280-24-046065.md) | [139 d](/filings/0001296445-26-000006.md) | [115](/filings/0001628280-25-023547.md) | [30.7 d](/filings/0001296445-25-000008.md) | [106 d](/filings/0001296445-25-000012.md) | [159 d](/filings/0001296445-26-000006.md) | [88.0](/filings/0001296445-26-000008.md) | [96.9 d](/filings/0001296445-26-000014.md) | [45.2 d](/filings/0001296445-25-000012.md) | [105 d](/filings/0001296445-26-000006.md) | [78.6](/filings/0001296445-26-000008.md) | [50.6 d](/filings/0001296445-26-000014.md) |
| Capital expenditure | $m | [182 d](/filings/0001628280-24-046065.md) | [170 d](/filings/0001296445-26-000006.md) | [103](/filings/0001628280-25-023547.md) | [147 d](/filings/0001296445-25-000008.md) | [110 d](/filings/0001296445-25-000012.md) | [128 d](/filings/0001296445-26-000006.md) | [193](/filings/0001296445-26-000008.md) | [135 d](/filings/0001296445-26-000014.md) | [147 d](/filings/0001296445-25-000012.md) | [145 d](/filings/0001296445-26-000006.md) | [114](/filings/0001296445-26-000008.md) | [138 d](/filings/0001296445-26-000014.md) |
| Dividends paid | $m | [7.2 d](/filings/0001628280-24-046065.md) | [7.2 d](/filings/0001296445-26-000006.md) | [7.2](/filings/0001628280-25-023547.md) | [7.3 d](/filings/0001296445-25-000008.md) | [7.3 d](/filings/0001296445-25-000012.md) | [7.3 d](/filings/0001296445-26-000006.md) | [7.3](/filings/0001296445-26-000008.md) | [7.3 d](/filings/0001296445-26-000014.md) | [7.3 d](/filings/0001296445-25-000012.md) | [7.2 d](/filings/0001296445-26-000006.md) | [7.5](/filings/0001296445-26-000008.md) | [7.2 d](/filings/0001296445-26-000014.md) |
| Share repurchases | $m | [0.0 d](/filings/0001437749-23-031120.md) | [0.0 d](/filings/0001628280-25-008531.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001296445-26-000008.md) | [0.0 d](/filings/0001296445-26-000014.md) | not reported | not reported | [24.4](/filings/0001296445-26-000014.md) | [(0.0) d](/filings/0001296445-26-000014.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [56.5](/filings/0001437749-23-031120.md) | [57.1](/filings/0001437749-24-015856.md) | [60.6](/filings/0001628280-24-035397.md) | [60.6](/filings/0001628280-24-046065.md) | [60.5](/filings/0001628280-25-023547.md) | [60.8](/filings/0001296445-25-000008.md) | [60.8](/filings/0001296445-25-000012.md) | [60.8](/filings/0001296445-26-000008.md) | [61.0](/filings/0001296445-26-000014.md) | [61.3](/filings/0001296445-25-000012.md) | [62.0](/filings/0001296445-26-000008.md) | [62.5](/filings/0001296445-26-000014.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 61,496,941 at 2026-08-01, from the cover of the [10-Q filed 2026-08-06](/filings/0001296445-26-000014.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.